Arvelle Therapeutics - Angelini Pharma Company

We are a Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders. Part of #AngeliniPharma

[International League Against Epilepsy @IlaeWeb]

IEC 2021 Industry Message:
Aiming for seizure freedom: a patient-centric approach to drug-resistant epilepsy.
@ArvelleTx
commitment for human beings who suffer from #epilepsy will be presented with a dedicated symposium at #IEC2021, 31 August, at 17:00 CEST.

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

🧪 Today new data are strengthening the confidence on new opportunities for people with #epilepsy.

A publication of long term safety and tolerability data of cenobamate was reported by @SKLifeScience.
Read more here >https://t.co/Temd7X1ruk

[European Academy of Neurology @EANeurology]

People with #epilepsy need a chance more for a good life.

Get more insights into the burden of uncontrolled seizures and the current treatments. Join "Raising the bar in drug-resistant focal onset seizures: any improvements in sight?" @AngeliniPharma
https://t.co/xbECdve9MU

[European Academy of Neurology @EANeurology]

Register for the #EAN2021 Virtual Congress!🧠
Become part of the biggest European event in neurology with an overarching theme ''Towards Precision Neurology'' #homeofneurology
Register here: https://t.co/70CEU53o5y

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

Today is International #EpilepsyDay 2021!

Thank you for making #50millionsteps a success and helping us to raise awareness in support of the 50 million people worldwide affected by epilepsy!

Visit https://t.co/tVw8XscqSh and https://t.co/AJtKw7QHnk

@IntEpilepsyDay

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

It's not easy living with #epilepsy but you can help make a difference.

Help us make a difference for those living with epilepsy by joining the #50millionsteps campaign for International #EpilepsyDay 2021.

Visit https://t.co/tVw8XscqSh and https://t.co/AJtKw7QHnk

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

Many of those living with #epilepsy feel isolated.

By taking a walk, you can join the #50millionsteps campaign for International #EpilepsyDay. Help patients feel less isolated by taking a step!

Visit https://t.co/tVw8XscqSh and https://t.co/AJtKw7QHnk

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

After two different anti-seizure medications, about 40% of epilepsy patients are drug resistant.

Help us make a difference by joining the #50millionsteps campaign for International #EpilepsyDay 2021.

Visit https://t.co/tVw8XscqSh and https://t.co/AJtKw7QHnk

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

Make a difference today for those living with #epilepsy by joining the #50millionsteps campaign for International #EpilepsyDay 2021.

For more information visit https://t.co/tVw8XscqSh and https://t.co/AJtKw7QHnk

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

6 million people in Europe suffer from #epilepsy. You can help make a difference. Just by taking a step, you can join the #50millionsteps campaign for International #EpilepsyDay 2021. For more information visit https://t.co/tVw8XscqSh & https://t.co/AJtKw7QHnk #epilepsyawareness

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

We are proud to announce that ONTOZRYTM (cenobamate) has received positive opinion from the @ema_news #CHMP for the adjunctive treatment of uncontrolled focal onset #seizures in adults.

Read more here: https://t.co/nbZ5I13tmS

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

Delighted to announce that @AngeliniPharma and Arvelle Therapeutics have agreed on a definitive merger agreement, valuating #Arvelle up to $960 million. Read the announcement here: https://t.co/LTCvHZLhek

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

As 2020 comes to an end, the team at Arvelle would like to wish everyone happy holidays and a peaceful New Year.

We hope you enjoy a restful break and look forward to staying connected as we embark into 2021 together.

#ArvelleTx

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

Join us for Epilepsy in Conversation - Session 3: A Neurologist’s Perspective tomorrow, Thursday 3 December from 15:00–15:45. Click here to view the agenda and register: https://t.co/s92aO38Ffp

#epilepsy #epilepsyinconversation #epilepsymedicaleducation #CNS #ArvelleTx

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

Join us for Epilepsy in Conversation - Session 2: A Nurse’s Perspective tomorrow, Thursday 26 November from 12:00–13:00. Click here to view the agenda and register: https://t.co/s92aO38Ffp

#epilepsy #epilepsyinconversation #epilepsymedicaleducation #CNS #ArvelleTx

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

Join us for Epilepsy in Conversation - Session 1: A Neurologist’s Perspective tomorrow, Tuesday 24 November from 12:00–13:00. Click here to view the agenda and register: https://t.co/s92aO38Ffp

#epilepsy #epilepsyinconversation #epilepsymedicaleducation #CNS #ArvelleTx

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

Join us for Epilepsy in Conversation, a series of virtual medical education workshops discussing epilepsy management. Sessions are Tuesday 24 Nov, Thursday 26 Nov, and Tuesday 3 Dec. Register here: https://t.co/s92aO38Ffp

#epilepsy #epilepsyinconversation #CNS #ArvelleTx

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

Danke #DGN2020 für einen erfolgreichen Kongress! Unser Symposium bot so viele interessante Highlights, unter anderem eine produktive Diskussion über die Auswirkungen der pharmakoresistenten #Epilepsie auf Patienten.

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

Heute ist es so weit! #DGN2020 ist in vollem Gange, und unser Symposium über die Herausforderungen und Risiken der pharmakoresistenten fokalen Epilepsie findet in nur wenigen Stunden statt. Das sollten Sie nicht verpassen, melden Sie sich jetzt an: https://t.co/nhM45sckWX @dgn_ev

[Arvelle Therapeutics - Angelini Pharma Company @AngeliniPhCh]

Rounding off our most recent additions to our Country Commercial team, we have welcomed Manuel Ortega as the new General Manager overseeing Spain & Portugal.
Welcome to the team, Manuel! #epilepsy #ArvelleTx #corporatenews #newhire